Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MVA HIV-1 vaccine
- Development stage
- Unknown
- Lead developer
- Swedish Institute for Infectious Disease Control
- Modality
- Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Intradermal
01
Overview
The MVA HIV-1 vaccine is an investigational recombinant viral vector vaccine based on the Modified Vaccinia Ankara (MVA) platform. Developed by the Swedish Institute for Infectious Disease Control (SMI), it is designed to prevent HIV-1 infection by expressing multiple HIV-1 antigens, including Env (gp120/gp160), Gag, Pol, Nef, Tat, and Rev. The vaccine aims to elicit robust cellular (T cell) and humoral (antibody) immune responses. In clinical studies such as the HIVIS07 trial, it has been evaluated as a heterologous boost following a DNA vaccine prime (HIVIS DNA), sometimes administered with dermal electroporation to enhance immunogenicity.
- Other names
- Modified Vaccinia Ankara HIV-1 vaccineMVA-HIV vaccinerecombinant MVA-HIV-1 vaccine
02
Targets
Vpu (HIV-1 Vpu)Human immunodeficiency virus type 1 reverse transcriptaseRev (HIV-1 Rev)Vif (HIV-1 Vif)Tat (HIV-1 Tat)Nef (HIV-1 Nef)Gag (HIV-1 Gag polyprotein)Vpr (HIV-1 Vpr)
Beyond the preview
Go deeper on MVA HIV-1 vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MVA HIV-1 vaccine.